

## 研究成果の刊行に関する一覧表

## 書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書 籍 名	出版社名	出版地	出版年	ページ

## 雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Suzuki-Muromoto S, Kosaki R, Kosaki K, Kubota M.	Familial hemiplegic migraine with a PRRT2 mutation: phenotypic variations and carbamazepine efficacy.	Brain Dev.	42(3)	293-297	2020
Yamashita Y, Ogawa T, Ogaki K, Kamo H, Sugiura T, Kitahara E, Izawa N, Iwamuro H, Oyama G, Kamagata K, Hatanoto T, Umemura A, Kosaki R, Kubota M, Shimizu Y, Hattori N	Neuroimaging evaluation and successful treatment by using directional deep brain stimulation and levodopa in a patient with GNAO1-associated movement disorder.	J Neurol Sci.	411	116710	2020
Kosaki R, Kubota M, Uehara T, Suzuki H, Takemouchi T, Kosaki K,	Consecutive Medical Expenditure Analysis at a Tertiary Center: Diagnostic and Health-economic Outcomes.	Am J Med Genet A.	182(7)	1601-1607	2020
Saettini F, Herriot R, Prada E, Nizon M, Zampieri D, Marzollo A, Romantziouk I, Lougaris V, Cortesi M, Morreale A, Kosaki R, Cardinale F, Ricci S, Domínguez-Garrido E, Montin D, Vincenti M, Milani D, Biondi A, Gervasini C, Badolati R.	Prevalence of Immunological Defects in a Cohort of 97 Rubinstein-Taybi Syndrome Patients.	J Clin Immunol.	10	1007/s10875-020-00808-4	2020

Saettini F, Herriot R, Prada E, Nizon M, Zama D, Marzollo A, Romanou I, Lougaris V, Cortesi M, Morreale A, Kosaki R, Cardinale F, Ricci S, Domínguez-Garrido E, Montin D, Vincent M, Milani D, Biondi A, Gervasini C, Badolati R.	Prevalence of Immunological Defects in a Cohort of 97 Rubinstein-Taybi Syndrome Patients.	J Clin Immunol.	10	1007/s10875-020-00808-4	2020
Takahashi Y, Kubota M, Kosaki R, Kosaki K, Ishiguro A.	A severe form of autosomal recessive spinocerebellar ataxia associated with novel PMPCA variants.	Brain Dev.	S0387-7604(20)	30318-1	2020
Ishikawa T, Tamura E, Kasahara M, Uchida H, Higuchi M, Kobayashi H, Shimizu H, Ogawa E, Yotani N, Irie R, Kosaki R, Kosaki K, Uchiyama T, Onodera M, Kawai T.	Severe Liver Disorder Following Liver Transplantation in STING-Associated Vasculopathy with Onset in Infancy.	J Clin Immunol.	10	1007/s10875-021-00977-w.	2021
小崎 里華	先天性疾患染色体検査検査値を読む 2020	内科	Vol.125p588(4)		2020
小崎 里華	本人に伝える遺伝カウンセリング	臨床遺伝学③ 専門医テキストシリーズ		小児領域	2021
Matsuo M, Nadanaka S, Soga M, Sugiyama T, Serigano S, Shimano K, Ichinose F, Takuji N, Maeda T, Houkin K, Era T, Kitagawa H.	Vulnerability to shear stress caused by altered periendothelial matrix is a key feature of Moyamoya disease.	Sci Rep	11	1552	2021
Kuzuya M, Takemoto M, Kubota Y, Taniguchi T, Motegi SI, Taniguchi A, Nakagami H, Maezawa Y, Koshizaka M, Kato H, Mori S, Tsukamoto K, Yokote K	Management guideline for Werner syndrome 2020. 2. Sarcopenia associated with Werner syndrome.	Geriatr Gerontol Int.	21(2)	139-141	2021
Kato H, Maezawa Y, Takayama N, Ouchi Y, Kaneko H, Kinoshita D, Takada-Watanabe A, Oshima M, Koshizaka M, Ogata H, Kubota Y, Mitsukawa N, Eto K, Iwama A, Yokote K.	Fibroblasts from different body parts exhibit distinct phenotypes in adult progeria Werner syndrome.	Aging (Albany NY).	13(4)	4946-4961	2021

Ishikawa T, Takemoto M, Akimoto Y, Takada-Watanabe A, Yan K, Sakamoto K, Maezawa Y, Suguro M, He L, Tryggvason K, Betsholtz C, Yokote K.	A novel podocyte protein, R3h domain containing, R3h-like, inhibits TGF- $\beta$ -induced p38 MAPK and regulates the structure of podocytes and glomerular basement membrane.	J Mol Med (Berl).			2021
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MT, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group.	Once-Weekly Semaglutide in Adults with Overweight or Obesity.	N Engl J Med	384(11)	989	2021
Koshizaka M, Maezawa Y, Maeda Y, Shoji M, Kato H, Kaneko H, Ishikawa T, Kinoshita D, Kobayashi K, Kawashima J, Sekiguchi A, Motegi SI, Nakagami H, Yamada Y, Tsukamoto S, Taniguchi A, Sugimoto K, Shoda Y, Hashimoto K, Yoshimura T, Suzuki D, Kuzuya M, Takemoto M, Yokote K.	Time gap between the onset and diagnosis in Werner syndrome: a nationwide survey and the 2020 registry in Japan.	Aging (Albany NY).	12(24)	24940-24956	2020
Taniguchi A, Tanaka Y, Takemoto M, Kubota Y, Taniguchi T, Motegi SI, Nakagami H, Maezawa Y, Koshizaka M, Kato H, Tsukamoto K, Mori S, Kuzuya M, Yokote K.	Management guideline for Werner syndrome 2020. 8. Calcification in tendons associated with Werner syndrome.	Geriatr Gerontol Int.	21(2)	163-165	2021
Tsukamoto K, Takemoto M, Kubota Y, Taniguchi T, Motegi SI, Taniguchi A, Nakagami H, Maezawa Y, Koshizaka M, Kato H, Mori S, Kuzuya M, Yokote K.	Management guideline for Werner syndrome 2020. 1. Dyslipidemia and fatty liver associated with Werner syndrome.	Geriatr Gerontol Int.	21(2)	133-138	2021
Kubota Y, Takemoto M, Taniguchi T, Motegi SI, Taniguchi A, Nakagami H, Maezawa Y, Koshizaka M, Kato H, Mori S, Kuzuya M, Yokote K.	Management guideline for Werner syndrome 2020. 6. Skin ulcers associated with Werner syndrome: Prevention and non-surgical and surgical treatment.	Geriatr Gerontol Int.	21(2)	153-159	2021

Takemoto M, Kubota Y, Taniguchi T, Motegi SI, Taniguchi A, Nakagami H, Maezawa Y, Koshizaka M, Kato H, Tsukamoto K, Mori S, Kuzuya M, Yokote K.	Management guideline for Werner syndrome 2020. 3. Diabetes associated with Werner syndrome.	Geriatr Gerontol Int.	21(2)	142-145	2021
Kuzuya M, Takemoto M, Kubota Y, Taniguchi T, Motegi SI, Taniguchi A, Nakagami H, Maezawa Y, Koshizaka M, Kato H, Mori S, Tsukamoto K, Yokote K.	Management guideline for Werner syndrome 2020. 2. Sarcopenia associated with Werner syndrome.	Geriatr Gerontol Int.	21(2)	139-141	2021
Mori S, Takemoto M, Kubota Y, Taniguchi T, Motegi SI, Taniguchi A, Nakagami H, Maezawa Y, Koshizaka M, Kato H, Tsukamoto K, Kuzuya M, Yokote K.	Management guideline for Werner syndrome 2020. 4. Osteoporosis associated with Werner syndrome.	Geriatr Gerontol Int.	21(2)	146-149	2021
Motegi SI, Takemoto M, Taniguchi T, Kubota Y, Taniguchi A, Nakagami H, Maezawa Y, Koshizaka M, Kato H, Mori S, Tsukamoto K, Kuzuya M, Yokote K.	Management guideline for Werner syndrome 2020. 7. Skin ulcer associated with Werner syndrome: Dermatological treatment.	Geriatr Gerontol Int.	21(2)	160-162	2021
Taniguchi T, Takemoto M, Kubota Y, Motegi SI, Taniguchi A, Nakagami H, Maezawa Y, Koshizaka M, Kato H, Mori S, Tsukamoto K, Kuzuya M, Yokote K.	Management guideline for Werner syndrome 2020. 5. Infection associated with Werner syndrome.	Geriatr Gerontol Int.	21(2)	150-152	2021
Takemoto M, Yokote K.	Preface to Management guideline for Werner syndrome 2020.	Geriatr Gerontol Int.	21(2)	131-132	2021
Koshizaka M, Ishikawa K, Ishibashi R, Takahashi S, Sakamoto K, Yoshino H, Baba Y, Ide S, Ide K, Ishikawa T, Onishi S, Kobayashi K, Takemoto M, Horikoshi T, Shimofusa R, Maezawa Y, Yokote K.	Comparison of Visceral Fat Reduction by Ipragliflozin and Metformin in Elderly Type 2 Diabetes Patients: Sub-Analysis of a Randomized-Controlled Study.	Diabetes Therapy	12(1)	183-196	2021

Yamashita S, Masuda D, Akishita M, Arai H, Asada Y, Dobashi K, Egashira K, Harada-Shibata M, Hirata K, Ishibashi S, Kajinami K, Kinoshita M, Kozaki K, Kuzuya M, Ogura M, Okamura T, Sato K, Shimano H, Tsukamoto K, Yokode M, Yokote K, Yoshida M.	Guidelines on the Clinical Evaluation of Medicinal Products for Treatment of Dyslipidemia.	J Atheroscler Thromb	27(11)	1246-1254	2020
Yamamoto R, Akasaki K, Horita M, Yonezawa M, Asakura H, Kanamori T, Maezawa Y, Koshizaka M, Yokote K, Kurita S.	Evaluation of glucose tolerance and effect of dietary management on increased visceral fat in a patient with Werner syndrome.	Endocr J	67(12)	1239-1246	2020
Minamizuka T, Kobayashi J, Tada H, Miyashita K, Koshizaka M, Maezawa Y, Ono H, Yokote K.	Detailed analysis of lipolytic enzymes in a Japanese woman of familial lipoprotein lipase deficiency - Effects of pemafibrate treatment.	Clin Chim Acta	510	216-219	2020
Koshizaka M, Ishikawa K, Ishibashi R, Maezawa Y, Sakamoto K, Uchiyama D, Nakamura S, Yanagisawa M, Yokoh H, Kobayashi A, Onishi S, Kobayashi K, Ogino J, Hatanaka N, Tokuyama H, Shimada F, Ohara E, Ishikawa T, Shoji M, Iwamoto S, Ide K, Baba Y, Hattori A, Kitamoto T, Horikoshi T, Shimofusa R, Takahashi S, Nagashima K, Sato Y, Takemoto M, Newby LK, Yokote K; PRIME-V study group.	Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Subanalysis of a prospective, randomized, controlled study (PRIME-V study).	J Diabetes Invest	12(2)	200-206	2021
Ishibashi R, Takatsuna Y, Koshizaka M, Tatsuomi T, Takahashi S, Nagashima K, Asami N, Arai M, Shimada F, Tachibana K, Watanabe Y, Ishikawa K, Hoshino A, Yamamoto K, Kubota A-Taniai M, Mayama T, Yamamoto S, Yokote K.	Safety and Efficacy of Ranibizumab and Luseogliflozin Combination Therapy in Patients with Diabetic Macular Edema: Protocol for a Multicenter, Open-Label Randomized Controlled Trial.	Diabetes Ther	11(8)	1891-1905	2020

<p>Yokote K, Niwa K, Hakoda T, Oh F, Kajimoto Y, Fukui T, Kim H, Noda Y, Lundström T, Yajima T.</p>	<p>Short-Term Efficacy (at 12 Weeks) and Long-Term Safety (up to 52 Weeks) of Omega-3 Free Fatty Acids (AZD0585) for the Treatment of Japanese Patients With Dyslipidemia - A Randomized, Double-Blind, Placebo-Controlled, Phase III Study.</p>	<p>Circ J</p>	<p>84(6)</p>	<p>994-1003</p>	<p>2020</p>
---	--	---------------	--------------	-----------------	-------------